Insider Selling: CeriBell (NASDAQ:CBLL) CTO Sells $131,753.52 in Stock

Key Points

• CTO Raymond Woo sold 4,887 CeriBell shares for about $131,754, reducing his stake by 2.35%; he retained 203,118 shares.
• CeriBell reported Q3 revenue of $29.34 million, slightly above expectations, but its loss per share of $0.55 was wider than the $0.51 consensus estimate.
• The company commercially launched a delirium-monitoring solution, expanding its brain-monitoring platform and creating a potential new revenue source.

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CTO Raymond Woo sold 4,887 shares of the company's stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $26.96, for a total transaction of $131,753.52. Following the completion of the transaction, the chief technology officer owned 203,118 shares in the company, valued at approximately $5,476,061.28. This represents a 2.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Raymond Woo also recently made the following trade(s):

• On Thursday, October 1st, Raymond Woo sold 4,887 shares of CeriBell stock. The shares were sold at an average price of $24.38, for a total value of $119,145.06.
• On Tuesday, September 8th, Raymond Woo sold 4,887 shares of CeriBell stock. The stock was sold at an average price of $24.33, for a total value of $118,900.71.
• On Friday, August 21st, Raymond Woo sold 1,979 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total transaction of $47,535.58.

CeriBell Stock Performance

Shares of CBLL traded down $0.78 during mid-day trading on Wednesday, hitting $27.50. 683,154 shares of the company's stock were exchanged, compared to its average volume of 367,620. CeriBell, Inc. has a 52 week low of $10.94 and a 52 week high of $28.89. The stock's 50-day simple moving average is $25.06 and its 200-day simple moving average is $20.85. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -15.63 and a beta of 0.86. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). The company had revenue of $29.34 million for the quarter, compared to the consensus estimate of $29.18 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. On average, equities research analysts expect that CeriBell, Inc. will post -1.96 EPS for the current year.

Analyst Ratings Changes

CBLL has been the subject of several recent analyst reports. TD Cowen upped their price objective on shares of CeriBell from $29.00 to $33.00 and gave the stock a "buy" rating in a research report on Friday, October 2nd. Barclays upgraded shares of CeriBell to a "neutral" rating in a research report on Tuesday, August 18th. Raymond James Financial reaffirmed a "strong-buy" rating and set a $29.00 price target on shares of CeriBell in a report on Thursday, September 3rd. Canaccord Genuity Group increased their price target on shares of CeriBell from $25.00 to $26.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. Finally, BTIG Research reissued a "buy" rating on shares of CeriBell in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, CeriBell has a consensus rating of "Moderate Buy" and an average price target of $27.00.

Key Headlines Impacting CeriBell

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: CeriBell commercially launched a delirium-monitoring solution, expanding its point-of-care brain-monitoring platform and adding a new potential source of revenue. Article: Ceribell Expands Its Point-of-Care Brain Monitoring Platform
• Positive Sentiment: Third-quarter revenue was $29.34 million, slightly ahead of analysts’ $29.18 million estimate. Zacks reported a loss of $0.48 per share versus its $0.50 consensus loss estimate. Article: CeriBell Reports Q3 Loss, Tops Revenue Estimates
• Negative Sentiment: The company reported a $21 million quarterly loss, with new-launch expenses contributing to the higher loss. Its reported EPS of -$0.55 missed the consensus estimate of -$0.51, while the per-share loss worsened from $0.37 a year earlier. Article: CeriBell Posts Higher Q3 Loss With New Launch Expenses
• Negative Sentiment: CTO Raymond Woo sold 4,887 shares for about $132,000. The sale reduced his holdings by 2.35%, though he retained 203,118 shares. SEC insider transaction filing

Institutional Trading of CeriBell

Institutional investors and hedge funds have recently modified their holdings of the business. Strs Ohio bought a new position in CeriBell in the first quarter valued at about $27,000. Legal & General Group Plc bought a new position in shares of CeriBell in the second quarter worth about $53,000. State of Wyoming bought a new position in shares of CeriBell in the first quarter worth about $62,000. Quantbot Technologies LP acquired a new stake in shares of CeriBell in the 2nd quarter valued at approximately $112,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of CeriBell in the 1st quarter valued at approximately $341,000.

About CeriBell

CeriBell, Inc is a medical technology company that develops artificial intelligence-enabled neurological diagnostic products. Its technology is designed to help healthcare professionals rapidly identify and monitor seizures, including nonconvulsive seizures that may be difficult to recognize through a standard clinical examination.

The company's primary product is the Ceribell Rapid Response EEG system, a portable electroencephalography platform that combines a wireless EEG recorder, a simplified disposable headband, and software-based analysis tools.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.